Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 28, 2006

AskBio and GSK Ink Gene Therapy Agreement

  • Asklepios Biopharmaceutical entered into a cross license agreement with GlaxoSmithKline to develop and commercialize gene therapy-based treatments.

    Through the agreement, AskBio will gain exclusive access to selected recombinant adeno-associated virus vector serotypes that GSK licensed from the University of Pennsylvania for the treatment of three orphan drug indications, including muscular dystrophy, heart failure suffered by muscular dystrophy patients, and hemophilia B.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.